Success Story: Overcoming RFE to Advance Medicinal Chemistry and Drug Discovery: EB1A Approval Secured for a Senior Research Scientist from India
Client’s Testimonial:
"Working with WeGreened on my EB-1A I-140 petition was a very positive experience. The team demonstrated strong expertise and remained clear, timely, and communicative throughout the entire process. They provided helpful guidance during both the initial petition preparation and the RFE stage, ensuring that everything was handled thoroughly and efficiently. I truly appreciate their professionalism, dedication, and attention to detail. I would confidently recommend WeGreened to anyone pursuing an EB-1A petition."
On June 30th, 2026, we received another EB1A (Alien of Extraordinary Ability) approval for a Senior Research Scientist in the field of Medicinal Chemistry (Approval Notice).
General Field: Medicinal Chemistry
Position at the Time of Case Filing: Senior Research Scientist
Country of Origin: India
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: June 30th, 2026
Processing Time: 3 months, 28 days (Premium Processing Requested)
Case Summary:
The client’s work addresses critical challenges in medicinal chemistry, particularly the design and application of chemical probes to target disease-relevant protein networks in cancer and neurodegenerative diseases. His proposed endeavor involved advancing small-molecule drug discovery and developing novel chemical probes for diagnostic and therapeutic applications. At the time of filing, he was employed as a Senior Research Scientist, where his work included chemical probe design, structure-activity relationship studies, synthetic methodology, and translational applications in biomedical research.
Research with National Importance
His research addresses a major public health challenge by advancing new approaches to diagnosing and treating cancer and neurodegenerative diseases. Through the development of disease-focused chemical probes and pharmaceutically relevant small molecules, his work supports precision drug discovery, translational biomedical research, and the advancement of therapeutic strategies with potential clinical relevance.
Academic Contributions and Recognition
At the time of filing, the client’s record included 29 peer-reviewed journal articles, 4 conference abstracts, 1 preprint, and 3 book chapters, collectively cited 1,015 times. Several of his papers ranked among the top 1% most cited in chemistry for their publication years. His publications have been widely relied upon by independent researchers internationally, including in applications involving PPI-targeting chemical probes, metal-catalyzed reactions, and PET imaging for Alzheimer’s disease. He also conducted at least 50 peer reviews for recognized journals in his field, demonstrating his expertise and influence in guiding research standards. In addition, his research tools and scientific contributions have supported ongoing translational research at multiple U.S. universities, further demonstrating the practical applicability and impact of his work beyond publications.
Recognition from Experts
Experts highlighted the significance of the client’s work and its potential impact on cancer therapeutics. This expert highlighted the client’s unique contributions and the broader impact of his research on advancing therapeutic strategies in medicinal chemistry.
One expert noted:
“...[client] is a vital member of the medicinal chemistry research community who addresses the need for tumor-selective therapeutic strategies, validated chemical probes targeting pathological chaperone networks, and frameworks linking post-translational modifications to drug design.”
This expert endorsement further reinforces the petition’s demonstration of the client’s extraordinary ability and the national importance of his research. Together with his publication record, citation impact, and international recognition, he demonstrated both scientific and practical significance.
EB1A Approval and Outlook
The I-140 EB1A petition was filed on March 2nd, 2026, with direct Premium Processing, and approved on June 30th, 2026. The petition overcame an RFE issued on March 20th, 2026, which requested additional clarification regarding the significance of his contributions and international recognition. The approval recognized the national importance of his work in medicinal chemistry, particularly his contributions to chemical probe development, small-molecule therapeutics, and translational research for cancer and neurodegenerative diseases.
This outcome supports the client’s continued efforts to advance medicinal chemistry, improve therapeutic strategies, and contribute to translational biomedical research in the United States. We congratulate him on this approval and wish him continued success in advancing drug discovery and clinical applications.